Expression, purification, biochemical and pharmacological characterization of a recombinant aprotinin variant

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 8, 2004, Pages 483-497

  Apeler, Heiner ^a   Peters, Jörg ^a   Schröder, Werner ^a   Schneider, Karl Heinz ^a   Lemm, Georg ^a   Hinz, Volker ^a   Rossouw, Gawie J ^b   Dembowsky, Klaus ^a,c  

^a BAYER PHARMA AG   (Germany)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c Ingenium Pharmaceuticals AG   (Germany)

Author keywords

Aprotinin, immunogenicity, recombinant variant, yeast expression; CAS 9087 70 1; Kunitz inhibitor; Subdural hematoma, rat

Indexed keywords

ANTIINFLAMMATORY AGENT; APROTININ; APROTININ VARIANT; KALLIKREIN; PLASMIN; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EDEMA; BRAIN WATER; CHIMPANZEE; CONTROLLED STUDY; CROSS REACTION; DOG; DRUG POTENCY; DRUG PURIFICATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; NONHUMAN; PROTEIN EXPRESSION; RABBIT; RAT; REFLEX; SACCHAROMYCES CEREVISIAE; SITE DIRECTED MUTAGENESIS; SUBDURAL HEMATOMA; SURFACE CHARGE;

EID: 4344700016     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297003     Document Type: Article

References (26)

1. Fritz, H., Wunder, G., Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneim.-Forsch./Drug Res. 33 (I), 479 (1983)
2. Dembowsky, K., Schröder, W., Aprotinin, recombinant aprotinin, and recombinant aprotinin mutants. In: K. Dembowsky, P. Stadler (eds.), Novel Therapeutic Proteins - Selected Case Studies, pp. 225-241. Wiley-VCH Verlag, Weinheim (2001)
3. Royston, D., High-dose aprotinin therapy: a review of the first five years' experience. J. Cardiothorac. Vasc. Anesth. 6, 76 (1992)
4. Peters, D. C., Noble, S., Aprotinin. An update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs 57, 233 (1999)
5. Beckmann, J., Mehlich, A., Schroeder, W. et al., Semi-synthesis of Arg15, Glu15, Met15 and Nle15-aprotinin involving enzymatic peptide bond resynthesis. J. Protein Chem. 8, 101 (1989)
6. 52]aprotinin. Biol. Chem. Hoppe-Seyler 369, 27 (1988)
7. Auerswald, E. A., Bruns, W., Hörlein, D. et al., Variants of bovine pancreatic Trypsin inhibitor produced by recombinant DNA technology, process, expression vector and recombinant host therefor and pharmaceutical use thereof. U.S. Pat. 5,707,568 (1995)
8. 15]aprotinin. Immunopharmacology 35, 221 (1997)
9. Björn, S. E., Norris, K., Nörskov-Lauritsen, L. et al., Aprotinin analogues. WO 92/06111 (1990)
10. Schröder, W., Björn, S. E., Norris, K. et al., Aprotininvarianten mit verbesserten Eigenschaften. EP 0 821 007 (1996)
11. Apeler, H., Beunink, J., Dörschug, M. et al., Process for preparing recombinant aprotinin and recombinant aprotinin variants having the natural N-terminal sequence. U.S. Pat. 5,707,831 (1995)
12. Wittmann-Liebold, B., Automated Microsequencing: Introduction and Overview. In: R. M. Kamp, T. Choli-Papadopoulou, B. Wittmann-Liebold (eds.), Protein Structure Analysis, pp. 107-136. Springer Verlag, Berlin-Heidelberg (1997)
13. Merril, C. R., Goldman, D., Sedman, S. A. et al., Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins. Science 211, 1437 (1981)
14. Laemmli, U. K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680 (1970)
15. Bieth, J. G., Some kinetic consequences of the tight binding of protein-proteinase-inhibitors to proteolytic enzymes and their application to the determination of dissociation constants. In: H. Fritz, H. Tschesche, L. J. Greene et al. (eds.), Bayer Symposium V: Proteinase inhibitors, pp. 463-469. Springer Verlag, Berlin-Heidelberg (1974)
16. Belorgey, D., Dirrig, S., Amouric, M. et al., Inhibition of human pancreatic proteinases by mucus proteinase inhibitor eglin c and aprotinin. Biochem. J. 313, 555 (1996)
17. Koibuchi, Y., Ichikawa, A., Nakagawa, M. et al., Histamine release induced from mast cells by active components of compound 48/80. Eur. J. Pharmacol. 115, 163 (1985)
18. Inase, N., Schreck, R. E., Lazarus, S. C., Heparin inhibits histamine release from canine cells. Am. J. Physiol. 264, L387 (1993)
19. Schuler, P., Herrnsdorf, J., Potentiometry. In: H. U. Bergmeyer, Methods of enzymatic analysis, pp. 368-397. Wiley-VCH Verlag, Weinheim (1983)
20. Miller, J. D., Bullock, R., Graham, D. I. et al., Ischemic brain damage in a model of acute subdural hematoma. Neurosurgery 27, 433 (1990)
21. Paxinos, G., Watson, C., The Rat Brain in Stereotaxtic Coordinates, 3rd ed. Academic Press, New York (1996)
22. Xi, G. H., Hua, Y., Keep, R. F. et al., Systemic complement depletion diminishes perihematomal brain edema in rats. Stroke 32, 162 (2001)
23. Eijkenboom, M., Gerlach, I., Jork, R. et al., Effects of subdural hematoma on sensorimotor functioning and spatial learning in rats. Neuropharmacology 39, 817 (2000)
24. Brake, A. J., α-Factor leader-directed secretion of heterologous proteins from yeast. Methods Enzymol. 185, 408 (1990)
25. Davis, R., Whittington, R., Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs 49, 954 (1995)
26. Leskiw, U., Levy, J. H., Antigenicity of protamine and aprotinin in cardiac surgery. In: R. Pifarre (ed.), Blood conservation with aprotinin, pp. 253-266. Hanley & Belfus, Philadelphia (1995)